# US 2025/0146077 A1 · Novel estrogen receptor mutations and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0146077 A1
- Document ID: US20250146077A1
- Status: Published application
- Kind: A1
- Application number: 18/828,966
- Filed: 2024-09-09
- Published: 2025-05-08
- Earliest claimed: 2011-10-14
- Assignees: Foundation Medicine, Inc.
- Applicants: Foundation Medicine, Inc.
- Inventors: Maureen T. CRONIN; Garrett Michael FRAMPTON; Doron LIPSON; Vincent A. MILLER; Gary PALMER; Jeffrey S. ROSS; Philip James STEPHENS; Roman YELENSKY
- Web page: https://patentgrep.com/patent/US20250146077A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/423: condensed with carbocyclic rings
- A61K 31/428: condensed with carbocyclic rings
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/472: Non-condensed isoquinolines, e.g. papaverine
- A61K 31/536: ortho- or peri-condensed with carbocyclic ring systems
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 31/567: substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 14/72: for hormones {(for neuromediators C07K14/70571)}
- C07K 16/2869: {against hormone receptors (for antibodies against neuromediator receptors C07K16/286)}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Novel mutant ESR1 molecules and uses are disclosed.

## Claims

### Claim at position 1

1-122. (canceled)

### Claim 123

A method of treating a subject having an Estrogen Receptor positive (ER+) breast cancer, comprising:
detecting in a sample from the subject a mutant estrogen receptor 1 (ESR1) polypeptide or a nucleic acid molecule encoding the mutant ESR1 polypeptide,
wherein the mutant ESR1 polypeptide, or the nucleic acid molecule encoding the ESR1 polypeptide, comprises one or more of:
one or more missense mutations at amino acid position 311, 341, 350, 394, 414, 433, 503, or 538 of the amino acid sequence of SEQ ID NO:2,
a deletion of nucleotides 1046-1051 of SEQ ID NO:1, or
an insertion between amino acid positions 344 and 345 of SEQ ID NO:2; and
administering to the subject an effective amount of a Selective Estrogen Receptor Degrader (SERD), thereby treating the ER+ breast cancer in the subject.

### Claim 124 (depends on 123)

The method of claim 123, wherein the mutant ESR1 polypeptide comprises one or more of:
an aspartate to glycine substitution at amino acid position 538 (D538G) of SEQ ID NO: 2;
a deletion of amino acids Leu-Ala-Asp (LAD) at positions 349-351 of SEQ ID NO:2;
an insertion of a histidine at amino acid position 349 of SEQ ID NO:2;
a threonine to methionine substitution at amino acid position 311 (T311M) of SEQ ID NO: 2;
a serine to leucine substitution at amino acid position 341 (S341L) of SEQ ID NO: 2;
an alanine to glutamate substitution at amino acid position 350 (A350E) of SEQ ID NO: 2;
an arginine to histidine substitution at amino acid position 394 (R394H) of SEQ ID NO:
2;
a glutamine substitution at amino acid position 414 of SEQ ID NO: 2;
a serine to proline substitution at amino acid position 433 (S433P) of SEQ ID NO: 2;
an arginine to tryptophan substitution at amino acid position 503 (R503W) of SEQ ID NO: 2; or
an insertion of a cysteine between amino acid positions 344 and 345 of SEQ ID NO:2.

### Claim 125 (depends on 123)

The method of claim 123, wherein said subject:
(i) has previously received a treatment with a SERM;
(ii) has failed a first or second line of treatment with a SERM;
(iii) is postmenopausal or premenopausal;
(iv) stops a treatment with a SERM prior to administration of the SERD;
(v) is premenopausal and an oophorectomy is performed on the subject;
or any combination of (i)-(v).

### Claim 126 (depends on 123)

The method of claim 123, wherein the subject is postmenopausal.

### Claim 127 (depends on 123)

The method of claim 123, wherein the SERD is fulvestrant.

### Claim 128 (depends on 123)

The method of claim 123, wherein the SERD is administered in combination with a different therapeutic agent or a different therapeutic modality.

### Claim 129 (depends on 128)

The method of claim 128, wherein the different therapeutic agent or modality is selected according to a determination of the presence of a mutation other than the mutant ESR1 polypeptide or the nucleic acid molecule encoding the mutant ESR1 polypeptide, and wherein the mutation other than the mutant ESR1 polypeptide or the nucleic acid molecule encoding the mutant ESR1 polypeptide is a HER2 mutation, a p53 mutation, a BRCA mutation, an NF1 mutation, an EGFR/myc mutation, a PIK3CA mutation, a CCND1 mutation, a CDH1 mutation, or any combination thereof.

### Claim 130 (depends on 123)

The method of claim 123, wherein the detecting step comprises determining the presence of the mutant ESR1 polypeptide or the nucleic acid molecule encoding the mutant ESR1 polypeptide by sequencing.

### Claim 131 (depends on 130)

The method of claim 130, wherein the sequencing is next-generation sequencing (NGS).

### Claim 132 (depends on 123)

The method of claim 123, wherein the subject was previously tested for the presence of a mutant ESR1 polypeptide or a nucleic acid molecule encoding the mutant ESR1 polypeptide, wherein the mutant ESR1 polypeptide or the nucleic acid molecule encoding the mutant ESR1 polypeptide was not detected during the previous testing.

### Claim 133 (depends on 123)

The method of claim 123, wherein the subject was previously tested or is being tested for the presence of a mutant ESR1 polypeptide or a nucleic acid molecule encoding the mutant ESR1 polypeptide at 6-month or one-year intervals.

### Claim 134 (depends on 123)

The method of claim 123, further comprising generating a personalized cancer treatment report, by:
obtaining the sample from the subject,
detecting the mutant ESR1 polypeptide or the nucleic acid molecule encoding the mutant ESR1 polypeptide in the sample, and
selecting a treatment based on the ESR1 mutation detected.

### Claim 135 (depends on 123)

The method of claim 123, further comprising:
(i) identifying, selecting, or obtaining information or knowledge that the subject has participated in a clinical trial or has been treated for cancer; and
(ii) acquiring genotype information that identifies a mutant ESR1 polypeptide or a nucleic acid molecule encoding the mutant ESR1 polypeptide as being in the subject,
wherein the presence of the mutant ESR1 polypeptide or the nucleic acid molecule encoding the mutant ESR1 polypeptide identifies the subject as having an increased risk for, or having, a cancer associated with the mutant ESR1 polypeptide or the nucleic acid molecule encoding the mutant ESR1 polypeptide.

### Claim 136 (depends on 123)

The method of claim 123, wherein the ER+ breast cancer is metastatic or advanced ER+ breast cancer.

### Claim 137 (depends on 123)

The method of claim 123, wherein the ER+ breast cancer is a localized ER+ breast cancer.

### Claim 138 (depends on 123)

The method of claim 123, further comprising, prior to the detecting, acquiring the sample from the subject.

### Claim 139 (depends on 123)

The method of claim 123, wherein the sample comprises one or more of: a tissue biopsy, whole blood, serum, plasma, buccal scrape, sputum, saliva, cerebrospinal fluid, urine, stool, circulating tumor cells, circulating nucleic acids, or bone marrow.

### Claim 140 (depends on 123)

The method of claim 123, wherein the sample comprises a tumor biopsy, circulating tumor cell, or circulating nucleic acids.

### Claim 141 (depends on 123)

The method of claim 123, further comprising identifying the subject as having breast cancer with ER+ status.

### Claim 142 (depends on 141)

The method of claim 141, wherein the subject is identified as having ER+ breast cancer by immunohistochemistry.
